Suggested Dosing
Insomnia
Dried strobile: 1.5-2 g
Extract combo with valerian: 60 mg
Suggested Uses
Anxiety, insomnia & other sleep disorders, restlessness, tension, excitability, ADHD, nervousness, and irritability
Efficacy
Possibly effective for mild sedation
Interactions
Interaction Checker
No Results

Contraindicated
Serious - Use Alternative
Significant - Monitor Closely
Minor

Contraindicated (0)
Serious - Use Alternative (0)
Monitor Closely (25)
- amobarbital
hops increases effects of amobarbital by pharmacodynamic synergism. Use Caution/Monitor. May enhance CNS depression.
- azelastine
hops increases effects of azelastine by pharmacodynamic synergism. Use Caution/Monitor. May enhance CNS depression.
- brompheniramine
hops increases effects of brompheniramine by pharmacodynamic synergism. Use Caution/Monitor. May enhance CNS depression.
- butabarbital
hops increases effects of butabarbital by pharmacodynamic synergism. Use Caution/Monitor. May enhance CNS depression.
- butalbital
hops increases effects of butalbital by pharmacodynamic synergism. Use Caution/Monitor. May enhance CNS depression.
- carbinoxamine
hops increases effects of carbinoxamine by pharmacodynamic synergism. Use Caution/Monitor. May enhance CNS depression.
- chloral hydrate
hops increases effects of chloral hydrate by pharmacodynamic synergism. Use Caution/Monitor. May enhance CNS depression.
- chlorpheniramine
hops increases effects of chlorpheniramine by pharmacodynamic synergism. Use Caution/Monitor. May enhance CNS depression.
- cinnarizine
hops increases effects of cinnarizine by pharmacodynamic synergism. Use Caution/Monitor. May enhance CNS depression.
- clemastine
hops increases effects of clemastine by pharmacodynamic synergism. Use Caution/Monitor. May enhance CNS depression.
- cyclizine
hops increases effects of cyclizine by pharmacodynamic synergism. Use Caution/Monitor. May enhance CNS depression.
- cyproheptadine
hops increases effects of cyproheptadine by pharmacodynamic synergism. Use Caution/Monitor. May enhance CNS depression.
- dexchlorpheniramine
hops increases effects of dexchlorpheniramine by pharmacodynamic synergism. Use Caution/Monitor. May enhance CNS depression.
- dexmedetomidine
hops increases effects of dexmedetomidine by pharmacodynamic synergism. Use Caution/Monitor. May enhance CNS depression.
- dimenhydrinate
hops increases effects of dimenhydrinate by pharmacodynamic synergism. Use Caution/Monitor. May enhance CNS depression.
- diphenhydramine
hops increases effects of diphenhydramine by pharmacodynamic synergism. Use Caution/Monitor. May enhance CNS depression.
- doxylamine
hops increases effects of doxylamine by pharmacodynamic synergism. Use Caution/Monitor. May enhance CNS depression.
- hydroxyzine
hops increases effects of hydroxyzine by pharmacodynamic synergism. Use Caution/Monitor. May enhance CNS depression.
- pentobarbital
hops increases effects of pentobarbital by pharmacodynamic synergism. Use Caution/Monitor. May enhance CNS depression.
- phenobarbital
hops increases effects of phenobarbital by pharmacodynamic synergism. Use Caution/Monitor. May enhance CNS depression.
- primidone
hops increases effects of primidone by pharmacodynamic synergism. Use Caution/Monitor. May enhance CNS depression.
- promethazine
hops increases effects of promethazine by pharmacodynamic synergism. Use Caution/Monitor. May enhance CNS depression.
- secobarbital
hops increases effects of secobarbital by pharmacodynamic synergism. Use Caution/Monitor. May enhance CNS depression.
- triclofos
hops increases effects of triclofos by pharmacodynamic synergism. Use Caution/Monitor. May enhance CNS depression.
- triprolidine
hops increases effects of triprolidine by pharmacodynamic synergism. Use Caution/Monitor. May enhance CNS depression.
Minor (0)
Adverse Effects
Frequency Not Defined
Contact dermatitis
Warnings
Contraindications
N/A
Pregnancy & Lactation
Pregnancy Category: N/A
Lactation: N/A
Pregnancy Categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk. C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done. D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk. X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist. NA: Information not available.Pharmacology
Metabolism: N/A
Excretion: N/A
Mechanism of Action
2-methyl-3-butene-2-ol has sedative properties